Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes
Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes.
Gliptins are popular because they're taken orally once a day...and rarely cause hypoglycemia or weight gain.
In fact, nearly one in four diabetes patients take a gliptin.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote